FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Maurizio D'Incalci

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Tumor Cells, Cultured

Disorders

Physiology

Procedures

Flow Cytometry

Co-author Network

Publications

TOP 3
Natalie Turner; Andrea Veronesi; Alberto Zambelli; Gianni Del Sal; Maurizio D'Incalci; Ilenia Migliaccio; Erica Moretti; Stefano Piccolo; Libero Santarpia; Olimpia Siclari; Angelo Di Leo
Targeting triple negative breast cancer: Is p53 the answer?
Maurizio D'Incalci; Roberta Frapolli; Giovanni Germano; Paola Allavena
New activities for the anti-tumor agent trabectedin: taking two birds with one stone.
Daniela D'Angelo; Maurizio D'Incalci; Francesco Esposito; Roberta Frapolli; Roberto Pacelli; Dario Palmieri; Sarah Uboldi; Eleonora Borbone; Alfredo Fusco
The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Maurizio D'Incalci (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Natalie Turner; Andrea Veronesi; Alberto Zambelli; Gianni Del Sal; Maurizio D'Incalci; Ilenia Migliaccio; Erica Moretti; Stefano Piccolo; Libero Santarpia; Olimpia Siclari; Angelo Di Leo
Targeting triple negative breast cancer: Is p53 the answer?
Cancer treatment reviews 2013;39(5):541-50.
2013: Maurizio D'Incalci; Roberta Frapolli; Giovanni Germano; Paola Allavena
New activities for the anti-tumor agent trabectedin: taking two birds with one stone.
Oncotarget 2013;4(4):496-7.
2013: Daniela D'Angelo; Maurizio D'Incalci; Francesco Esposito; Roberta Frapolli; Roberto Pacelli; Dario Palmieri; Sarah Uboldi; Eleonora Borbone; Alfredo Fusco
The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin.
European journal of cancer (Oxford, England : 1990) 2013;49(5):1142-51.
2013: Giovanni Germano; Manuela Liguori; Alberto Mantovani; Sergio Marchini; Roberta Mortarini; Manuela Nebuloni; Fabio Pasqualini; Samantha Pesce; Silvana Pilotti; Roberta Sanfilippo; Sarah Uboldi; Nico van Rooijen; Massimo Zucchetti; Andrea Anichini; Achille Anselmo; Cristina Belgiovine; Luca Beltrame; Paolo G Casali; Maurizio D'Incalci; Eugenio Erba; Roberta Frapolli; Ilaria Fuso Nerini; Carlos M Galmarini; Paola Allavena
Role of macrophage targeting in the antitumor activity of trabectedin.
Cancer cell 2013;23(2):249-62.
2013: Ezia Bello; Alexander Berndt; Gabriella Camboni; Ennio Cavalletti; Gennaro Colella; Maurizio D'Incalci; Daniele Forestieri; Raffaella Giavazzi; Simonetta A Licandro; Petra Richter; Giulia Taraboletti; Massimo Zucchetti; Giovanna Damia
The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.
Molecular cancer therapeutics 2013;12(2):131-40.
2013: Elisa Gallerani; Dagmar Hess; Elena Marangon; Silvia Marsoni; Giovanni Martinelli; Cristina Noberasco; Federica Sala; Steffen Böhm; Dario Brunelli; Roberta Cereda; Filippo de Braud; Angelo Delmonte; Maurizio D'Incalci; Christopher Driessen; Massimo Zucchetti; Cristiana Sessa
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.
European journal of cancer (Oxford, England : 1990) 2013;49(2):290-6.
2013: Sergio Marchini; Rodolfo Milani; Ilaria Fuso Nerini; Luca Porcu; Michela Romano; Chiara Romualdi; Mauro Signorelli; Valter Torri; Alberto Zambelli; Silvana di Giandomenico; Luca Beltrame; Giorgio Cattoretti; Duccio Cavalieri; giovanna chiorino; Luca Clivio; Robert Fruscio; Costantino Mangioni; Maurizio D'Incalci
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer.
European journal of cancer (Oxford, England : 1990) 2013;49(2):520-30.
2012: Giovanna Damia; Gabriella Camboni; Gennaro Colella; Maurizio D'Incalci
Is PDGFR an important target for E-3810?
Journal of cellular and molecular medicine 2012;16(11):2838-9.
2012: Sergio Marchini; Luca Porcu; Elizabeth Poynor; Michela Romano; Richard R Barakat; Cecilia Bussani; Giorgio Cattoretti; Michela Cinquini; Luca Clivio; Maurizio D'Incalci; Eugenio Erba; Robert Fruscio; Dionyssios Katsaros; Andrew Koff; Lucio Luzzatto
The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(16):4313-24.
2012: Angela Maria Di Francesco; Maurizio D'Incalci; Daniela Meco; Filomena Pierri; Claudio Pisano; Giuseppe Barone; Gabriella Cusano; Anna Rita Torella; Paolo Ubezio; Riccardo Riccardi
Enhanced cell cycle perturbation and apoptosis mediate the synergistic effects of ST1926 and ATRA in neuroblastoma preclinical models.
Investigational new drugs 2012;30(4):1319-30.
2012: Giuseppina Della Vittoria Scarpati; Maurizio D'Incalci; Francesca Falcetta; Sergio Marchini; Chiara Carlomagno; Sabino De Placido; Alfonso De Stefano; Vijay Kumar Singh; Paolo Ubezio; Stefano Pepe
A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
International journal of radiation oncology, biology, physics 2012;83(4):1113-9.
2012: S Uboldi; A J Watson; S Di Giandomenico; S Bernasconi; A M Caccuri; O Capozzi; giovanna chiorino; L Clivio; Giovanna Damia; Eugenio Erba; A Fossati; I Fuso Nerini; M Ganzinelli; Federica Grosso; Roberto Mantovani; Elena Marangon; Sergio Marchini; G P Margison; A Pastore; M Rocchi; M Romano; F Sala; J C Tercero; Maurizio D'Incalci
Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.
International journal of cancer. Journal international du cancer 2012;131(1):59-69.
2012: Federica Grosso; Vicente Alfaro; Mirela Cartoafa; Maurizio D'Incalci; Carlos Fernández-Teruel; Javier Gómez; Carmen Kahatt; Pilar Lardelli; Antonio Nieto; Elena Roy; Arturo Soto-Matos; Ian Judson
A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin.
Cancer chemotherapy and pharmacology 2012;69(6):1557-65.
2012: Ghassan M Sulaiman; Sarah Uboldi; Ali H Ad'hiah; Khulood W Al-Sammarrae; Renzo Bagnati; Ezia Bello; Eugenio Erba; Roberta Frapolli; Nicolò Panini; Marzia Pezzolato; Michela Romano; Eugenio Scanziani; Maurizio D'Incalci
Assessing the anti-tumour properties of Iraqi propolis in vitro and in vivo.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2012;50(5):1632-41.
2012: Sarah Uboldi; Luca Beltrame; Enrica Calura; Duccio Cavalieri; giovanna chiorino; Daniela D'Angelo; Maurizio D'Incalci; Eugenio Erba; Ilaria Fuso Nerini; Sergio Marchini; Paola Ostano; Chiara Romualdi
A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.
PloS one 2012;7(4):e35423.
2012: Rebecca A Mosig; Ravi Sachidanandam; Peter Schlosshauer; Emir Senturk; Hardik Shah; Samantha Cohen; Maurizio D'Incalci; PR Dottino; Robert Fruscio; Fei Huang; Li Lin; Sergio Marchini; John A Martignetti
Application of RNA-Seq transcriptome analysis: CD151 is an Invasion/Migration target in all stages of epithelial ovarian cancer.
Journal of ovarian research 2012;5():4.
2012: Rebecca A Mosig; Ravi Sachidanandam; Emir Senturk; Hardik Shah; Eugene Chudin; Samantha Cohen; Maurizio D'Incalci; PR Dottino; Robert Fruscio; Mollie Lobl; Sergio Marchini; John A Martignetti
IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer.
Journal of ovarian research 2012;5(1):3.
2011: Roberta Sanfilippo; Angelo Paolo Dei Tos; Susana Banerjee; Maurizio D'Incalci; Federica Grosso; Robin L Jones; Ian Judson; Silvana Pilotti; Francesco Raspagliesi; Paolo G Casali
Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.
Gynecologic oncology 2011;123(3):553-6.
2011: Federica Sala; Renzo Bagnati; Roberta Cereda; Maurizio D'Incalci; Valeria Livi; Massimo Zucchetti
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study.
Journal of mass spectrometry : JMS 2011;46(10):1039-45.
2011: Katherine S Lovejoy; Eric Raymond; Maria Serova; Ivan Bieche; Massimo Broggini; Esteban Cvitkovic; Maurizio D'Incalci; Shahin Emami; Eugenio Erba; Sandrine Faivre; Christian Gespach; Stephen J Lippard
Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells.
Molecular cancer therapeutics 2011;10(9):1709-19.
2011: Federica Grosso; Maurizio D'Incalci
Problems in dealing with very rare adverse effects of new anticancer drugs: the example of trabectedin.
Tumori 2011;97(2):256.
2011: Sergio Marchini; Duccio Cavalieri; Robert Fruscio; Enrica Calura; Daniela Garavaglia; Ilaria Fuso Nerini; Costantino Mangioni; Giorgio Cattoretti; Luca Clivio; Luca Beltrame; Dionyssios Katsaros; Luca Scarampi; Guido Menato; Patrizia Perego; Giovanna Chiorino; Alessandro Buda; Chiara Romualdi; Maurizio D'Incalci
Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.
The lancet oncology 2011;12(3):273-85.
2011: Ezia Bello; Gennaro Colella; Valentina Scarlato; Paolo Oliva; Alexander Berndt; Giovanni Valbusa; Sonia Colombo Serra; Maurizio D'Incalci; Ennio Cavalletti; Raffaella Giavazzi; Giovanna Damia; Gabriella Camboni
E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.
Cancer research 2011;71(4):1396-405.
2011: Valentina Colombo; Monica Lupi; Francesca Falcetta; Daniele Forestieri; Maurizio D'Incalci; Paolo Ubezio
Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells.
Cancer chemotherapy and pharmacology 2011;67(2):369-79.
2010: E Salvati; Marco Scarsella; M Porru; A Rizzo; S Iachettini; L Tentori; G Graziani; Maurizio D'Incalci; Malcolm F G Stevens; A Orlandi; D Passeri; Eric Gilson; Gabriella Zupi; Carlo Leonetti; Annamaria Biroccio
PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy.
Oncogene 2010;29(47):6280-93.
2010: Federica Sala; Elena Marangon; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maurizio D'Incalci; Massimo Zucchetti
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study.
Journal of mass spectrometry : JMS 2010;45(11):1299-305.
2010: Roberta Frapolli; Elena Tamborini; Emanuela Virdis; Ezia Bello; Eva Tarantino; Sergio Marchini; Federica Grosso; Roberta Sanfilippo; Alessandro Gronchi; Juan Carlos Tercero; Gabriella Peloso; Paolo Casali; Silvana Pilotti; Maurizio D'Incalci
Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(20):4958-67.
2010: G Damia; Maurizio D'Incalci
Genetic instability influences drug response in cancer cells.
Current drug targets 2010;11(10):1317-24.
2010: Massimo Zucchetti; Daniela Meco; Angela Maria Di Francesco; Tiziana Servidei; Valentina Patriarca; Gabriella Cusano; Maurizio D'Incalci; Daniele Forestieri; Claudio Pisano; Riccardo Riccardi
Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts.
Cancer chemotherapy and pharmacology 2010;66(4):635-41.
2010: Maurizio D'Incalci; Carlos M Galmarini
A review of trabectedin (ET-743): a unique mechanism of action.
Molecular cancer therapeutics 2010;9(8):2157-63.
2010: Claudio Pisano; Loredana Vesci; Ferdinando Maria Milazzo; Mario Berardino Guglielmi; Rosanna Foderà; Marcella Barbarino; Maurizio D'Incalci; Massimo Zucchetti; Giovanna Petrangolini; Monica Tortoreto; Paola Perego; Valentina Zuco; Augusto Orlandi; Daniela Passeri; Paolo Carminati; Claudio Cavazza; Franco Zunino
Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(15):3944-53.
2010: Ilaria Cervellini; Ezia Bello; Roberta Frapolli; Carla Porretta-Serapiglia; Norberto Oggioni; Annalisa Canta; Raffaella Lombardi; Francesca Camozzi; Ilaria Roglio; Roberto Cosimo Melcangi; Maurizio D'Incalci; Giuseppe Lauria; Pietro Ghezzi; Guido Cavaletti; Roberto Bianchi
The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats.
Neurotoxicity research 2010;18(2):151-60.
2010: Paolo G Casali; Roberta Sanfilippo; Maurizio D'Incalci
Trabectedin therapy for sarcomas.
Current opinion in oncology 2010;22(4):342-6.
2010: Dario Brunelli; Michele Tavecchio; Cristiano Falcioni; Roberta Frapolli; Eugenio Erba; Renato Iori; Patrick Rollin; Jessica Barillari; Carla Manzotti; Paolo Morazzoni; Maurizio D'Incalci
The isothiocyanate produced from glucomoringin inhibits NF-kB and reduces myeloma growth in nude mice in vivo.
Biochemical pharmacology 2010;79(8):1141-8.
2010: Giovanni Germano; Roberta Frapolli; Matteo Simone; Michele Tavecchio; Eugenio Erba; Samantha Pesce; Fabio Pasqualini; Federica Grosso; Roberta Sanfilippo; Paolo G Casali; Alessandro Gronchi; Emanuela Virdis; Eva Tarantino; Silvana Pilotti; Angela Greco; Manuela Nebuloni; Carlos Maria Galmarini; Juan Carlos Tercero; Alberto Mantovani; Maurizio D'Incalci; Paola Allavena
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
Cancer research 2010;70(6):2235-44.
2010: Roberta Frapolli; Massimo Zucchetti; Cristiana Sessa; Silvia Marsoni; Lucia Viganò; Alberta Locatelli; Eliana Rulli; Anna Compagnoni; Ezia Bello; Claudio Pisano; Paolo Carminati; Maurizio D'Incalci
Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.
European journal of cancer (Oxford, England : 1990) 2010;46(3):505-16.
2010: Cristina Belgiovine; Roberta Frapolli; Katiuscia Bonezzi; Ilaria Chiodi; Francesco Favero; Maurizia Mello-Grand; Angelo P Dei Tos; Elena Giulotto; Giulia Taraboletti; Maurizio D'Incalci; Chiara Mondello
Reduced expression of the ROCK inhibitor Rnd3 is associated with increased invasiveness and metastatic potential in mesenchymal tumor cells.
PloS one 2010;5(11):e14154.
2010: Amalia Azzariti; Letizia Porcelli; Grazia M Simone; Anna E Quatrale; Nicola A Colabufo; Francesco Berardi; Roberto Perrone; Massimo Zucchetti; Maurizio D'Incalci; Jian Ming Xu; angelo paradiso
Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
Cancer chemotherapy and pharmacology 2010;65(2):335-46.
2009: Elena Marangon; Cristiano Falcioni; Carla Manzotti; Gabriele Fontana; Maurizio D'Incalci; Massimo Zucchetti
Development and validation of a LC-MS/MS method for the determination of the novel oral 1,14 substituted taxane derivatives, IDN 5738 and IDN 5839, in mouse plasma and its application to the pharmacokinetic study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(32):4147-53.
2009: Marta Cesca; Roberta Frapolli; Alexander Berndt; Valentina Scarlato; Petra Richter; Hartwig Kosmehl; Maurizio D'Incalci; Anderson Ryan; Raffaella Giavazzi
The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
Neoplasia (New York, N.Y.) 2009;11(11):1155-64.
2009: Giovanna Damia; Maurizio D'Incalci
Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models?
European journal of cancer (Oxford, England : 1990) 2009;45(16):2768-81.
2009: Federica Sala; Massimo Zucchetti; Renzo Bagnati; Maurizio D'Incalci; Silvia Pace; Francesca Capocasa; Elena Marangon
Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of ST1926, a novel oral antitumor agent, adamantyl retinoid derivative, in plasma of patients in a Phase I study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(27):3118-26.
2009: Angela Rizzo; Erica Salvati; Manuela Porru; Carmen D'Angelo; Malcolm F Stevens; Maurizio D'Incalci; Carlo Leonetti; Eric Gilson; Gabriella Zupi; Annamaria Biroccio
Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway.
Nucleic acids research 2009;37(16):5353-64.
2009: Fredrik Mertens; Cristina R Antonescu; Peter Hohenberger; Marc Ladanyi; Piergiorgio Modena; Maurizio D'Incalci; Paolo G Casali; Massimo Aglietta; Thor Alvegård
Translocation-related sarcomas.
Seminars in oncology 2009;36(4):312-23.
2009: Federica Grosso; R Sanfilippo; E Virdis; C Piovesan; Paola Collini; Palma Dileo; C Morosi; J C Tercero; José Jimeno; Maurizio D'Incalci; Alessandro Gronchi; Silvana Pilotti; Paolo G Casali
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(8):1439-44.
2009: Cristiana Sessa; Sara Cresta; Cristina Noberasco; Giuseppe Capri; E Gallerani; Filippo de Braud; Massimo Zucchetti; Maurizio D'Incalci; Alberta Locatelli; Silvia Marsoni; I Corradino; C Minoia; P Zintl; Luca Gianni
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.
European journal of cancer (Oxford, England : 1990) 2009;45(12):2116-22.
2009: Paolo Ubezio; Monica Lupi; Davide Branduardi; Paolo Cappella; Edoardo Cavallini; Valentina Colombo; Giada Matera; Claudia Natoli; Daniela Tomasoni; Maurizio D'Incalci
Quantitative assessment of the complex dynamics of G1, S, and G2-M checkpoint activities.
Cancer research 2009;69(12):5234-40.
2009: Claudia Forni; Mario Minuzzo; Emanuela Virdis; Elena Tamborini; Matteo Simone; Michele Tavecchio; Eugenio Erba; Federica Grosso; Alessandro Gronchi; Pierre Aman; Paolo Casali; Maurizio D'Incalci; Silvana Pilotti; Roberto Mantovani
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.
Molecular cancer therapeutics 2009;8(2):449-57.
2009: Maurizio D'Incalci
Adjuvant 5-FU based chemotherapy for colon cancer: match or miss the mismatch?
European journal of cancer (Oxford, England : 1990) 2009;45(3):316-7.
2008: Sergio Marchini; Pietro Mariani; giovanna chiorino; Eleonora Marrazzo; Riccardo Bonomi; Robert Fruscio; Luca Clivio; Annalisa Garbi; Valter Torri; Michela Cinquini; Tiziana Dell'Anna; Giovanni Apolone; Massimo Broggini; Maurizio D'Incalci
Analysis of gene expression in early-stage ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7850-60.
2008: Carlo Leonetti; Marco Scarsella; Giuseppe Riggio; Angela Rizzo; Erica Salvati; Maurizio D'Incalci; Lidia Staszewsky; Roberta Frapolli; Malcolm F G Stevens; Antonella Stoppacciaro; Marcella Mottolese; Barbara Antoniani; Eric Gilson; Gabriella Zupi; Annamaria Biroccio
G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(22):7284-91.
2008: Michele Tavecchio; Matteo Simone; Eugenio Erba; I Chiolo; Giordano Liberi; Marco Foiani; Maurizio D'Incalci; Giovanna Damia
Role of homologous recombination in trabectedin-induced DNA damage.
European journal of cancer (Oxford, England : 1990) 2008;44(4):609-18.
2008: Elena Marangon; Federica Sala; Orazio Caffo; Enzo Galligioni; Maurizio D'Incalci; Massimo Zucchetti
Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
Journal of mass spectrometry : JMS 2008;43(2):216-23.
2007: Michele Tavecchio; Claudia Natoli; Paolo Ubezio; Eugenio Erba; Maurizio D'Incalci
Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.
Cell proliferation 2007;40(6):885-904.
2007: Erica Salvati; Carlo Leonetti; Angela Rizzo; Marco Scarsella; Marcella Mottolese; rossella galati; Isabella Sperduti; Malcolm F G Stevens; Maurizio D'Incalci; Maria Blasco; giovanna chiorino; Serge Bauwens; Béatrice Horard; Eric Gilson; Antonella Stoppacciaro; Gabriella Zupi; Annamaria Biroccio
Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect.
The Journal of clinical investigation 2007;117(11):3236-47.
2007: Marianna Paulis; Mirella Bensi; Donata Orioli; Chiara Mondello; Giuliano Mazzini; Maurizio D'Incalci; Cristiano Falcioni; Enrico Radaelli; Eugenio Erba; Elena Raimondi; Luigi De Carli
Transfer of a human chromosomal vector from a hamster cell line to a mouse embryonic stem cell line.
Stem cells (Dayton, Ohio) 2007;25(10):2543-50.
2007: Giovanna Damia; Maurizio D'Incalci
Targeting DNA repair as a promising approach in cancer therapy.
European journal of cancer (Oxford, England : 1990) 2007;43(12):1791-801.
2007: Federica Grosso; Robin L Jones; George D Demetri; Ian R Judson; Jean-Yves Blay; Axel Le Cesne; Roberta Sanfilippo; Paola Casieri; Paola Collini; Palma Dileo; Carlo Spreafico; Silvia Stacchiotti; Elena Tamborini; Juan C Tercero; José Jimeno; Maurizio D'Incalci; Alessandro Gronchi; Jonathan A Fletcher; Silvana Pilotti; Paolo G Casali
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
The lancet oncology 2007;8(7):595-602.
2007: Maurizio D'Incalci
Nitrosoureas: molecular pharmacology/ translational research.
Tumori 2007;93(3):suppl 17-21.
2007: Maurizio D'Incalci; William P Steward; Andreas J Gescher
Modulation of response to cancer chemotherapeutic agents by diet constituents: is the available evidence sufficiently robust for rational advice for patients?
Cancer treatment reviews 2007;33(3):223-9.
2007: Roberto Bianchi; Alessandra Gilardini; Virginia Rodriguez-Menendez; Norberto Oggioni; Annalisa Canta; Tina Colombo; Giulia De Michele; Sara Martone; Alessandra Sfacteria; Giuseppe Piedemonte; Giovanni Grasso; Patrizia Beccaglia; Pietro Ghezzi; Maurizio D'Incalci; Giuseppe Lauria; Guido Cavaletti
Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth.
European journal of cancer (Oxford, England : 1990) 2007;43(4):710-7.
2007: Guido Cavaletti; Alessandra Gilardini; Annalisa Canta; Laura Rigamonti; Virginia Rodriguez-Menendez; Cecilia Ceresa; Paola Marmiroli; Mario Bossi; Norberto Oggioni; Maurizio D'Incalci; Roland De Coster
Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.
Experimental neurology 2007;204(1):317-25.
2007: Cristiana Sessa; Sara Cresta; Thomas Cerny; J Baselga; E Rota Caremoli; A Malossi; D Hess; J Trigo; Massimo Zucchetti; Maurizio D'Incalci; alberto zaniboni; Giuseppe Capri; B Gatti; P Carminati; Claudio Zanna; Silvia Marsoni; Luca Gianni
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(3):561-8.
2007: Angela Maria Di Francesco; Daniela Meco; Anna Rita Torella; Giuseppe Barone; Maurizio D'Incalci; Claudio Pisano; Paolo Carminati; Riccardo Riccardi
The novel atypical retinoid ST1926 is active in ATRA resistant neuroblastoma cells acting by a different mechanism.
Biochemical pharmacology 2007;73(5):643-55.
2007: Carlo Gambacorti-Passerini; Lucia Tornaghi; Elena Marangon; Anna Franceschino; Enrico Pogliani; Maurizio D'Incalci; Massimo Zucchetti
Imatinib concentrations in human milk.
Blood 2007;109(4):1790.
2007: Maurizio D'Incalci; D Brunelli; Elena Marangon; Matteo Simone; Michele Tavecchio; A Gescher; R Mantovani
Modulation of gene transcription by natural products--a viable anticancer strategy.
Current pharmaceutical design 2007;13(27):2744-50.
2006: Roberta Frapolli; Elena Marangon; Marco Zaffaroni; Tina Colombo; C Falcioni; Renzo Bagnati; Matteo Simone; Maurizio D'Incalci; Carla Manzotti; Gabriele Fontana; Paolo Morazzoni; Massimo Zucchetti
Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(12):2028-35.
2006: Robert Fruscio; Andrea Lissoni; Roberta Frapolli; Silvia Corso; Costantino Mangioni; Maurizio D'Incalci; Massimo Zucchetti
Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients.
Cancer chemotherapy and pharmacology 2006;58(3):319-25.
2006: Annamaria Biroccio; Angela Rizzo; Raffaella Elli; Catherine-Elaine Koering; Aurélie Belleville; Barbara Benassi; Carlo Leonetti; Malcolm F G Stevens; Maurizio D'Incalci; Gabriella Zupi; Eric Gilson
TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells.
European journal of cancer (Oxford, England : 1990) 2006;42(12):1881-8.
2006: Federica Grosso; Palma Dileo; R Sanfilippo; Silvia Stacchiotti; Rossella Bertulli; C Piovesan; José Jimeno; Maurizio D'Incalci; A Gescher; Paolo G Casali
Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.
European journal of cancer (Oxford, England : 1990) 2006;42(10):1484-90.
2006: Clarissa Gerhauser; Helmut Bartsch; James Crowell; Silvio De Flora; Maurizio D'Incalci; Christian Dittrich; Norbert Frank; Enrico Mihich; Christian Steffen; Giampaolo Tortora; Andreas J Gescher
Development of novel cancer chemopreventive agents in Europe--neglected Cinderella or rising phoenix? A critical commentary. ESF Workshop on Cancer Chemoprevention, DKFZ, Heidelberg, September 18-20, 2005.
European journal of cancer (Oxford, England : 1990) 2006;42(10):1338-43.
2006: Maurizio D'Incalci
Correlation of ErbB2 gene status, mRNA and protein expression.
Onkologie 2006;29(6):246-7.
2006: Chiara Mondello; Samantha Zongaro; Maurizio D'Incalci
Telomerase expression in somatic cells: fountain of youth or Damocles' sword?
Cell cycle (Georgetown, Tex.) 2006;5(5):465-6.
2006: John Smyth; Jaap Verweij; Maurizio D'Incalci; Lekshmy Balakrishnan
"The Art of Successful Publication" ECCO 13 workshop report.
European journal of cancer (Oxford, England : 1990) 2006;42(4):434-6.
2006: Carmelo Rizzari; Marco Citterio; Massimo Zucchetti; Valentino Conter; Robert Chiesa; Antonella Colombini; Silvia Malguzzi; Daniela Silvestri; Maurizio D'Incalci
A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
Haematologica 2006;91(1):24-31.
2006: Richard D Verschoyle; Peter Greaves; Hong Cai; Arndt Borkhardt; Massimo Broggini; Maurizio D'Incalci; Edward S Riccio; Rupa Doppalapudi; Izet M Kapetanovic; William P Steward; Andreas J Gescher
Preliminary safety evaluation of the putative cancer chemopreventive agent tricin, a naturally occurring flavone.
Cancer chemotherapy and pharmacology 2006;57(1):1-6.
2005: Samantha Zongaro; Elisa de Stanchina; Tina Colombo; Maurizio D'Incalci; Elena Giulotto; Chiara Mondello
Stepwise neoplastic transformation of a telomerase immortalized fibroblast cell line.
Cancer research 2005;65(24):11411-8.
2005: Maria Cristina Manara; Stefania Perdichizzi; Massimo Serra; R Pierini; Stefania Benini; Claudia M Hattinger; Annalisa Astolfi; R Bagnati; Maurizio D'Incalci; Piero Picci; Katia Scotlandi
The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71.
International journal of oncology 2005;27(6):1605-16.
2005: Gianluca Tognon; Sergio Bernasconi; Nicola Celli; Glynn Faircloth; Carmen Cuevas; José Jimeno; Eugenio Erba; Maurizio D'Incalci
Induction of resistance to Aplidin in a human ovarian cancer cell line related to MDR expression.
Cancer biology & therapy 2005;4(12):1325-30.
2005: Maurizio D'Incalci; William P Steward; Andreas J Gescher
Use of cancer chemopreventive phytochemicals as antineoplastic agents.
The lancet oncology 2005;6(11):899-904.
2005: Mario Minuzzo; Michele Ceribelli; Marià Pitarque-Martì; Serena Borrelli; Eugenio Erba; Alberto DiSilvio; Maurizio D'Incalci; Roberto Mantovani
Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters.
Molecular pharmacology 2005;68(5):1496-503.
2005: Angela Maria Di Francesco; Anna Riccardi; Anna Shirley Riccardi; Giuseppe Barone; Sergio Rutella; Daniela Meco; Roberta Frapolli; Massimo Zucchetti; Maurizio D'Incalci; Claudio Pisano; Paolo Carminati; Riccardo Riccardi
The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.
Biochemical pharmacology 2005;70(8):1125-36.
2005: Matteo Simone; Eugenio Erba; Giovanna Damia; Faina Vikhanskaya; Angela M Di Francesco; Riccardo Riccardi; Christian Bailly; Carmen Cuevas; José Maria Fernandez Sousa-Faro; Maurizio D'Incalci
Variolin B and its derivate deoxy-variolin B: new marine natural compounds with cyclin-dependent kinase inhibitor activity.
European journal of cancer (Oxford, England : 1990) 2005;41(15):2366-77.
2005: Anna Riccardi; Daniela Meco; Paolo Ubezio; Giorgio Mazzarella; Mirko Marabese; Glynn Faircloth; José Jimeno; Maurizio D'Incalci; Riccardo Riccardi
Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.
Anti-cancer drugs 2005;16(8):811-5.
2005: Maurizio D'Incalci; Gabriella Zupi
Are we close to the clinical development of novel drugs targeting telomeres and telomerase?
European journal of cancer (Oxford, England : 1990) 2005;41(7):970.
2005: Paola Allavena; Mauro Signorelli; Marcello Chieppa; Eugenio Erba; Giancarlo Bianchi; Federica Marchesi; Chiara Omero Olimpio; Claudia Bonardi; Annalisa Garbi; Andrea Lissoni; Filippo de Braud; José Jimeno; Maurizio D'Incalci
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production.
Cancer research 2005;65(7):2964-71.
2005: Cristiana Sessa; Filippo de Braud; Antonella Perotti; Jean Bauer; Giuseppe Curigliano; Cristina Noberasco; FLAVIA ZANABONI; Luca Gianni; Silvia Marsoni; José Jimeno; Maurizio D'Incalci; Elisa Dall'ó; Nicoletta Colombo
Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(9):1867-74.
2005: Sergio Marchini; Eleonora Marrazzo; R Bonomi; giovanna chiorino; Marco Zaffaroni; Lawrence Weissbach; Francis J Hornicek; Massimo Broggini; Glynn Faircloth; Maurizio D'Incalci
Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743.
European journal of cancer (Oxford, England : 1990) 2005;41(2):323-33.
2004: Maurizio D'Incalci; Matteo Simone; Michele Tavecchio; Giovanna Damia; Annalisa Garbi; Eugenio Erba
New drugs from the sea.
Journal of chemotherapy (Florence, Italy) 2004;16 Suppl 4():86-9.
2004: Carlo Leonetti; Sarah Amodei; Carmen D'Angelo; Angela Rizzo; Barbara Benassi; Anna Antonelli; Raffaella Elli; Malcolm F G Stevens; Maurizio D'Incalci; Gabriella Zupi; Annamaria Biroccio
Biological activity of the G-quadruplex ligand RHPS4 (3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate) is associated with telomere capping alteration.
Molecular pharmacology 2004;66(5):1138-46.
2004: Sarah Donald; Richard D Verschoyle; Peter Greaves; Tina Colombo; Massimo Zucchetti; Cristiano Falcioni; Marco Zaffaroni; Maurizio D'Incalci; Margaret M Manson; José Jimeno; William P Steward; Andreas J Gescher
Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma.
International journal of cancer. Journal international du cancer 2004;111(6):961-7.
2004: Giulia Taraboletti; Maura Poli; Romina Dossi; Luigi Manenti; Patrizia Borsotti; Glynn Faircloth; Massimo Broggini; Maurizio D'Incalci; Dragana Vukasovic; Raffaella Giavazzi
Antiangiogenic activity of aplidine, a new agent of marine origin.
British journal of cancer 2004;90(12):2418-24.
2004: Monica Lupi; Giada Matera; Davide Branduardi; Maurizio D'Incalci; Paolo Ubezio
Cytostatic and cytotoxic effects of topotecan decoded by a novel mathematical simulation approach.
Cancer research 2004;64(8):2825-32.
2004: Nicola Celli; Barbara Mariani; Francesco Di Carlo; Massimo Zucchetti; Luis Lopez-Lazaro; Maurizio D'Incalci; Domenico Rotilio
Determination of aplidin, a marine-derived anticancer drug, in human plasma, whole blood and urine by liquid chromatography with electrospray ionisation tandem mass spectrometric detection.
Journal of pharmaceutical and biomedical analysis 2004;34(3):619-30.
2004: Eugenio Erba; E Cavallaro; Giovanna Damia; Roberto Mantovani; A di Silvio; A M Di Francesco; R Riccardi; Carmen Cuevas; Glynn Faircloth; Maurizio D'Incalci
The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.
Oncology research 2004;14(11-12):579-87.
2004: Gianluca Tognon; Roberta Frapolli; Marco Zaffaroni; Eugenio Erba; Massimo Zucchetti; Glynn Faircloth; Maurizio D'Incalci
Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin), an example of potential problems for extrapolation of active drug concentrations from in vitro studies.
Cancer chemotherapy and pharmacology 2004;53(1):89-90.
2003: Maurizio D'Incalci; José Jimeno
Preclinical and clinical results with the natural marine product ET-743.
Expert opinion on investigational drugs 2003;12(11):1843-53.
2003: Marco Zaffaroni; C Mucignat; Teresa Pecere; Giuseppe Zagotto; Roberta Frapolli; Maurizio D'Incalci; Massimo Zucchetti
High-performance liquid chromatographic assay for the determination of Aloe Emodin in mouse plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;796(1):113-9.
2003: Sarah Donald; Richard D Verschoyle; Peter Greaves; Timothy W Gant; Tina Colombo; Marco Zaffaroni; Roberta Frapolli; Massimo Zucchetti; Maurizio D'Incalci; Daniela Meco; Riccardo Riccardi; Luis Lopez-Lazaro; José Jimeno; Andreas J Gescher
Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat.
Cancer research 2003;63(18):5902-8.
2003: Chiara Mondello; Massimo Chiesa; Paola Rebuzzini; Samantha Zongaro; Annalisa Verri; Tina Colombo; Elena Giulotto; Maurizio D'Incalci; Claudio Franceschi; Fiorella Nuzzo
Karyotype instability and anchorage-independent growth in telomerase-immortalized fibroblasts from two centenarian individuals.
Biochemical and biophysical research communications 2003;308(4):914-21.
2003: Maurizio D'Incalci; Tina Colombo; Paolo Ubezio; Ines Nicoletti; Raffaella Giavazzi; Eugenio Erba; L Ferrarese; Daniela Meco; Riccardo Riccardi; C Sessa; E Cavallini; José Jimeno; Glynn Faircloth
The combination of yondelis and cisplatin is synergistic against human tumor xenografts.
European journal of cancer (Oxford, England : 1990) 2003;39(13):1920-6.
2003: Carlo Gambacorti-Passerini; Rocco Piazza; Maurizio D'Incalci
Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels.
Blood 2003;102(5):1933-4; author reply 1934-5.
2003: Eugenio Erba; Marta Serafini; Giuseppe Gaipa; Gianluca Tognon; Sergio Marchini; Nicola Celli; Domenico Rotilio; Massimo Broggini; José Jimeno; Glynn Faircloth; Andrea Biondi; Maurizio D'Incalci
Effect of Aplidin in acute lymphoblastic leukaemia cells.
British journal of cancer 2003;89(4):763-73.
2003: Daniela Meco; Tina Colombo; Paolo Ubezio; Massimo Zucchetti; Marco Zaffaroni; Anna Riccardi; Glynn Faircloth; Jimeno Jose; Maurizio D'Incalci; Riccardo Riccardi
Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies.
Cancer chemotherapy and pharmacology 2003;52(2):131-8.
2003: Graziella Pratesi; Diletta Laccabue; Cinzia Lanzi; Giuliana Cassinelli; Rosanna Supino; Massimo Zucchetti; Roberta Frapolli; Maurizio D'Incalci; Ezio Bombardelli; Paolo Morazzoni; Antonella Riva; Franco Zunino
IDN 5390: an oral taxane candidate for protracted treatment schedules.
British journal of cancer 2003;88(6):965-72.
2003: Annamaria Biroccio; Chiara Gabellini; Sarah Amodei; Barbara Benassi; Donatella Del Bufalo; Raffaella Elli; Anna Antonelli; Maurizio D'Incalci; Gabriella Zupi
Telomere dysfunction increases cisplatin and ecteinascidin-743 sensitivity of melanoma cells.
Molecular pharmacology 2003;63(3):632-8.
2003: Carlo Gambacorti-Passerini; Massimo Zucchetti; Domenico Russo; Roberta Frapolli; Magda Verga; Silvia Bungaro; Lucia Tornaghi; Fabio Rossi; Pietro Pioltelli; Enrico Pogliani; Daniele Alberti; Gianmarco Corneo; Maurizio D'Incalci
Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):625-32.
2003: Massimo Broggini; Sergio Marchini; Emanuela Galliera; Patrizia Borsotti; Giulia Taraboletti; Eugenio Erba; Marina Sironi; José Jimeno; Glynn Faircloth; Raffaella Giavazzi; Maurizio D'Incalci
Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4.
Leukemia 2003;17(1):52-9.
2002: Katia Scotlandi; Stefania Perdichizzi; Maria Cristina Manara; Massimo Serra; Stefania Benini; Vanessa Cerisano; Rosaria Strammiello; Mario Mercuri; Gemma Reverter-Branchat; Glynn Faircloth; Maurizio D'Incalci; Piero Picci
Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(12):3893-903.
2002: Marco Zaffaroni; Roberta Frapolli; Tina Colombo; Robert Fruscio; Ezio Bombardelli; Paolo Morazzoni; Antonella Riva; Maurizio D'Incalci; Massimo Zucchetti
High-performance liquid chromatographic assay for the determination of the novel C-Seco-taxane derivative (IDN 5390) in mouse plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;780(1):93-8.
2002: Maurizio D'Incalci
Professor Maurizio D'Incalci interviewed by Emma Cannell.
European journal of cancer (Oxford, England : 1990) 2002;38(12):1559.
2002: Massimo Rizzi; Silvio Caccia; Giovanna Guiso; Cristina Richichi; Jan A Gorter; Eleonora Aronica; Marisa Aliprandi; Renzo Bagnati; Roberto Fanelli; Maurizio D'Incalci; Rosario Samanin; Annamaria Vezzani
Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2002;22(14):5833-9.
2002: Sergio Marchini; giovanna chiorino; Glynn Faircloth; Maurizio D'Incalci
Changes in gene expression profile induced by the anticancer agent Aplidine in Molt-4 leukemic cell lines.
Journal of biological regulators and homeostatic agents 2002;16(3):241-8.
2002: Carlo Gambacorti-Passerini; Philipp le Coutre; Massimo Zucchetti; Maurizio D'Incalci
Binding of imatinib by alpha(1)-acid glycoprotein.
Blood 2002;100(1):367-8; author reply 368-9.
2002: Maurizio D'Incalci
Editorial comment on "In vitro toxicity of ET-743 and Aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors: comparison with the clinical results" by Albella and colleagues.
European journal of cancer (Oxford, England : 1990) 2002;38(10):1297.
2002: Eugenio Erba; L Bassano; G Di Liberti; Ivan Muradore; giovanna chiorino; Paolo Ubezio; Sara Vignati; Annamaria Codegoni; Maria Alfonsina Desiderio; Glynn Faircloth; José Jimeno; Maurizio D'Incalci
Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine.
British journal of cancer 2002;86(9):1510-7.
2002: Carlo Gambacorti-Passerini; Fabio Rossi; Magda Verga; Holger Ruchatz; Rosalind H Gunby; Roberta Frapolli; Massimo Zucchetti; Leonardo Scapozza; Silvia Bungaro; Lucia Tornaghi; Fabio Rossi; Pietro Pioltelli; Enrico Pogliani; Maurizio D'Incalci; Gianmarco Corneo
Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients.
Blood cells, molecules & diseases 2002;28(3):361-72.
2002: Cristina Geroni; Sergio Marchini; Paolo Cozzi; Emanuela Galliera; Enzio Ragg; Tina Colombo; Rosangela Battaglia; Martin Howard; Maurizio D'Incalci; Massimo Broggini
Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
Cancer research 2002;62(8):2332-6.
2002: Maurizio D'Incalci; Eugenio Erba; Giovanna Damia; Emanuela Galliera; Laura Carrassa; Sergio Marchini; Roberto Mantovani; Gianluca Tognon; Robert Fruscio; José Jimeno; Glynn Faircloth
Unique features of the mode of action of ET-743.
The oncologist 2002;7(3):210-6.
2001: Diletta Laccabue; Monica Tortoreto; Silvia Veneroni; Paola Perego; Eugenio Scanziani; Massimo Zucchetti; Marco Zaffaroni; Maurizio D'Incalci; Ezio Bombardelli; Franco Zunino; Graziella Pratesi
A novel taxane active against an orthotopically growing human glioma xenograft.
Cancer 2001;92(12):3085-92.
2001: Sergio Marchini; Massimo Broggini; C Sessa; Maurizio D'Incalci
Development of distamycin-related DNA binding anticancer drugs.
Expert opinion on investigational drugs 2001;10(9):1703-14.
2001: Paolo Cappella; Daniela Tomasoni; Mario Faretta; Monica Lupi; F Montalenti; F Viale; F Banzato; Maurizio D'Incalci; Paolo Ubezio
Cell cycle effects of gemcitabine.
International journal of cancer. Journal international du cancer 2001;93(3):401-8.
2001: Giovanna Damia; S Silvestri; Laura Carrassa; L Filiberti; Glynn Faircloth; Giordano Liberi; Marco Foiani; Maurizio D'Incalci
Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways.
International journal of cancer. Journal international du cancer 2001;92(4):583-8.
2001: Cristina Sottani; Tina Colombo; Massimo Zucchetti; Robert Fruscio; Maurizio D'Incalci; Claudio Minoia
High-performance liquid chromatography/tandem mass spectrometry for the quantitative analysis of a novel taxane derivative (BAY59-8862) in biological samples and characterisation of its metabolic profile in rat bile samples.
Rapid communications in mass spectrometry : RCM 2001;15(19):1807-16.
2001: Giovanna Damia; L Filiberti; Faina Vikhanskaya; Laura Carrassa; Y Taya; Maurizio D'Incalci; Massimo Broggini
Cisplatinum and taxol induce different patterns of p53 phosphorylation.
Neoplasia (New York, N.Y.) 2001;3(1):10-6.
2001: Eugenio Erba; D Bergamaschi; L Bassano; Giovanna Damia; Simona Ronzoni; Glynn Faircloth; Maurizio D'Incalci
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
European journal of cancer (Oxford, England : 1990) 2001;37(1):97-105.
2000: Massimo Broggini; G Buraggi; Ambrogio Brenna; L Riva; Annamaria Codegoni; Valter Torri; Andrea Lissoni; Costantino Mangioni; Maurizio D'Incalci
Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients.
Anticancer research 2000;20(6C):4835-40.
2000: Carlo Gambacorti-Passerini; R Barni; Philipp le Coutre; Massimo Zucchetti; G Cabrita; Loredana Cleris; Fabio Rossi; E Gianazza; Josef Brueggen; Robert Cozens; Pietro Pioltelli; Enrico Pogliani; Gianmarco Corneo; Franca Formelli; Maurizio D'Incalci
Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.
Journal of the National Cancer Institute 2000;92(20):1641-50.
2000: Olivia Pagani; Cristiana Sessa; Franco Nolè; Diana Crivellari; D Lombardi; Beat Thürlimann; D Hess; Markus M Borner; J Bauer; Giovanni Martinelli; Rossella Graffeo; Massimo Zucchetti; Maurizio D'Incalci; Aron Goldhirsch
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(8):985-91.
2000: Mario Minuzzo; Sergio Marchini; Massimo Broggini; Glynn Faircloth; Maurizio D'Incalci; Roberto Mantovani
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(12):6780-4.
2000: G Conforti; Tiziana Nardo; Maurizio D'Incalci; Miria Stefanini
Proneness to UV-induced apoptosis in human fibroblasts defective in transcription coupled repair is associated with the lack of Mdm2 transactivation.
Oncogene 2000;19(22):2714-20.
2000: P De Feudis; Sara Vignati; C Rossi; T Mincioni; Raffaella Giavazzi; Maurizio D'Incalci; Massimo Broggini
Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis.
Neoplasia (New York, N.Y.) 2000;2(3):202-7.
2000: Eugenio Erba; D Bergamaschi; L Bassano; Simona Ronzoni; G Di Liberti; Ivan Muradore; Sara Vignati; Glynn Faircloth; José Jimeno; Maurizio D'Incalci
Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743).
British journal of cancer 2000;82(10):1732-9.
2000: D Polizzi; Graziella Pratesi; SV Monestiroli; Monica Tortoreto; Franco Zunino; Ezio Bombardelli; Antonella Riva; Paolo Morazzoni; Tina Colombo; Maurizio D'Incalci; Massimo Zucchetti
Oral efficacy and bioavailability of a novel taxane.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):2070-4.
2000: Maria Ines Nicoletti; Tina Colombo; C Rossi; C Monardo; S Stura; Massimo Zucchetti; Antonella Riva; Paolo Morazzoni; M B Donati; Ezio Bombardelli; Maurizio D'Incalci; Raffaella Giavazzi
IDN5109, a taxane with oral bioavailability and potent antitumor activity.
Cancer research 2000;60(4):842-6.
2000: Carmelo Rizzari; Massimo Zucchetti; Valentino Conter; Luisa Diomede; A Bruno; L Gavazzi; M Paganini; P Sparano; Luca Lo Nigro; Maurizio Aricò; M Milani; Maurizio D'Incalci
L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(2):189-93.
2000: Faina Vikhanskaya; Maurizio D'Incalci; Massimo Broggini
p73 competes with p53 and attenuates its response in a human ovarian cancer cell line.
Nucleic acids research 2000;28(2):513-9.
2000: L Fumagalli; Massimo Zucchetti; I Parisi; M G Viganò; B Zecca; A Careddu; Maurizio D'Incalci; Adriano Lazzarin
The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma.
Cancer chemotherapy and pharmacology 2000;45(6):495-501.
1999: Tina Colombo; Roberta Frapolli; Ezio Bombardelli; Paolo Morazzoni; Antonella Riva; Maurizio D'Incalci; Massimo Zucchetti
High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma.
Journal of chromatography. B, Biomedical sciences and applications 1999;736(1-2):135-41.
1999: Nicola Celli; A M Gallardo; C Rossi; Massimo Zucchetti; Maurizio D'Incalci; Domenico Rotilio
Analysis of aplidine (dehydrodidemnin B), a new marine-derived depsipeptide, in rat biological fluids by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Biomedical sciences and applications 1999;731(2):335-43.
1999: Annamaria Codegoni; F Bertoni; C Patregnani; E Marinetti; Maurizio D'Incalci; Massimo Broggini
Allelic expression of p73 in human ovarian cancers.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(8):949-53.
1999: M Gander; Serge Leyvraz; Laurent A Decosterd; M Bonfanti; Catia Marzolini; F Shen; D Liénard; Lucien Perey; G Colella; Jérôme Biollaz; Ferdy Lejeune; Daniel B Yarosh; M Belanich; Maurizio D'Incalci
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(7):831-8.
1999: M Bonfanti; E La Valle; J M Fernandez Sousa Faro; Glynn Faircloth; Giuseppina Caretti; Roberto Mantovani; Maurizio D'Incalci
Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA.
Anti-cancer drug design 1999;14(3):179-86.
1999: Sergio Marchini; M Cirò; F Gallinari; Cristina Geroni; Paolo Cozzi; Maurizio D'Incalci; Massimo Broggini
Alpha-bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity.
British journal of cancer 1999;80(7):991-7.
1999: Eugenio Erba; D Bergamaschi; Simona Ronzoni; Mario Faretta; S Taverna; M Bonfanti; Carlo V Catapano; Glynn Faircloth; José Jimeno; Maurizio D'Incalci
Mode of action of thiocoraline, a natural marine compound with anti-tumour activity.
British journal of cancer 1999;80(7):971-80.
1999: Eugenio Erba; Simona Ronzoni; L Bassano; Raffaella Giavazzi; Maurizio D'Incalci
The metalloproteinase inhibitor batimastat (BB-94) causes cell cycle phase perturbations in ovarian cancer cells.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(5):589-91.
1999: G Colella; Sergio Marchini; Maurizio D'Incalci; R Brown; Massimo Broggini
Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents.
British journal of cancer 1999;80(3-4):338-43.
1999: Tina Colombo; I Parisi; Massimo Zucchetti; C Sessa; A Goldhirsch; Maurizio D'Incalci
Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(4):391-5.
1999: Faina Vikhanskaya; G Colella; M Valenti; Stefano Parodi; Maurizio D'Incalci; Massimo Broggini
Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(4):937-41.
1999: Annamaria Codegoni; F Bertoni; G Colella; G Caspani; L Grassi; Maurizio D'Incalci; Massimo Broggini
Microsatellite instability and frameshift mutations in genes involved in cell cycle progression or apoptosis in ovarian cancer.
Oncology research 1999;11(7):297-301.
1999: Cristiana Sessa; Massimo Zucchetti; Michele Ghielmini; J Bauer; Maurizio D'Incalci; J de Jong; H Naegele; S Rossi; M A Pacciarini; L Domenigoni; Franco Cavalli
Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243).
Cancer chemotherapy and pharmacology 1999;44(5):403-10.
1999: Massimo Zucchetti; Amerigo Boiardi; A Silvani; I Parisi; S Piccolrovazzi; Maurizio D'Incalci
Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin.
Cancer chemotherapy and pharmacology 1999;44(2):173-6.
1999: D Bergamaschi; Simona Ronzoni; S Taverna; Mario Faretta; P De Feudis; Glynn Faircloth; José Jimeno; Eugenio Erba; Maurizio D'Incalci
Cell cycle perturbations and apoptosis induced by isohomohalichondrin B (IHB), a natural marine compound.
British journal of cancer 1999;79(2):267-77.
1998: Maurizio D'Incalci; J Schüller; Tina Colombo; Massimo Zucchetti; Antonella Riva
Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
Seminars in oncology 1998;25(6 Suppl 13):16-20.
1998: G Damia; G Guidi; Maurizio D'Incalci
Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines.
European journal of cancer (Oxford, England : 1990) 1998;34(11):1783-8.
1998: Maurizio D'Incalci; M Bonfanti; A Pifferi; E Mascellani; G Tagliabue; D Berger; H H Fiebig
The antitumour activity of alkylating agents is not correlated with the levels of glutathione, glutathione transferase and O6-alkylguanine-DNA-alkyltransferase of human tumour xenografts. EORTC SPG and PAMM Groups.
European journal of cancer (Oxford, England : 1990) 1998;34(11):1749-55.
1998: Annamaria Codegoni; Maria Ines Nicoletti; G Buraggi; G Valoti; Raffaella Giavazzi; Maurizio D'Incalci; Fabio Landoni; Andrea Maneo; Massimo Broggini
Molecular characterisation of a panel of human ovarian carcinoma xenografts.
European journal of cancer (Oxford, England : 1990) 1998;34(9):1432-8.
1998: G Valoti; Maria Ines Nicoletti; A Pellegrino; J Jimeno; H Hendriks; Maurizio D'Incalci; Glynn Faircloth; Raffaella Giavazzi
Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1977-83.
1998: Faina Vikhanskaya; Sara Vignati; P Beccaglia; C Ottoboni; P Russo; Maurizio D'Incalci; Massimo Broggini
Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis.
Experimental cell research 1998;241(1):96-101.
1998: G Colella; Faina Vikhanskaya; Annamaria Codegoni; Cristina Bonazzi; Maurizio D'Incalci; Massimo Broggini
hMLH1 and hMSH2 expression and BAX frameshift mutations in ovarian cancer cell lines and tumors.
Carcinogenesis 1998;19(4):691-4.
1998: Sergio Marchini; Paolo Cozzi; Italo Beria; Cristina Geroni; L Capolongo; Maurizio D'Incalci; Massimo Broggini
Sequence-specific DNA alkylation of novel tallimustine derivatives.
Anti-cancer drug design 1998;13(3):193-205.
1998: Annamaria Codegoni; S Castagna; Costantino Mangioni; Anna Scovassi; Massimo Broggini; Maurizio D'Incalci
DNA-topoisomerase I activity and content in epithelial ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(3):313-9.
1998: M G Donelli; M Zucchetti; Elisabetta Munzone; Maurizio D'Incalci; A Crosignani
Pharmacokinetics of anticancer agents in patients with impaired liver function.
European journal of cancer (Oxford, England : 1990) 1998;34(1):33-46.
1998: Cristina Sottani; Claudio Minoia; Maurizio D'Incalci; M Paganini; Massimo Zucchetti
High-performance liquid chromatography tandem mass spectrometry procedure with automated solid phase extraction sample preparation for the quantitative determination of paclitaxel (Taxol) in human plasma.
Rapid communications in mass spectrometry : RCM 1998;12(5):251-5.
1997: C Filippini; M Bisiach; G Tagliabue; Maurizio D'Incalci; Paolo Ubezio
Hematopoietic toxicity and cell cycle perturbations induced by new DNA minor groove-alkylating agents.
International journal of cancer. Journal international du cancer 1997;72(5):801-9.
1997: Maurizio D'Incalci; C Sessa
DNA minor groove binding ligands: a new class of anticancer agents.
Expert opinion on investigational drugs 1997;6(7):875-84.
1997: M Bonfanti; G Colella; Massimo Broggini; Maurizio D'Incalci
Effect of G:C-->A:T transition, potentially arising from O6-guanine alkylation, in the transcription regulation of c-fos serum response element.
Anticancer research 1997;17(3C):2019-24.
1997: M Bonfanti; S Taverna; M Salmona; Maurizio D'Incalci; Massimo Broggini
p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth.
Cancer research 1997;57(8):1442-6.
1997: Annamaria Codegoni; Massimo Broggini; M R Pitelli; M Pantarotto; Valter Torri; Costantino Mangioni; Maurizio D'Incalci
Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer.
Gynecologic oncology 1997;65(1):130-7.
1997: D Debernardis; E G Siré; P De Feudis; Faina Vikhanskaya; M Valenti; P Russo; Stefano Parodi; Maurizio D'Incalci; Massimo Broggini
p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel.
Cancer research 1997;57(5):870-4.
1997: G Tagliabue; C Filippini; Paolo Ubezio; Maurizio D'Incalci
Combination of the new minor groove alkylator tallimustine and melphalan.
European journal of cancer (Oxford, England : 1990) 1997;33(2):284-7.
1997: Mario Faretta; D Bergamaschi; Simona Ronzoni; Maurizio D'Incalci; Eugenio Erba
Differences in cyclin B1 expression in cells blocked in the G2M phase after treatment with anticancer agent. New three-parametric flow cytometric analysis.
European journal of histochemistry : EJH 1997;41 Suppl 2():73-4.
1997: D Bergamaschi; Mario Faretta; Simona Ronzoni; S Taverna; P De Feudis; M Bonfanti; G Guidi; M Faircloth; José Jimeno; Maurizio D'Incalci; Eugenio Erba
Flow cytometric analysis of cell cycle phase perturbations induced by Thiocoraline, a new marine-derived anticancer compound.
European journal of histochemistry : EJH 1997;41 Suppl 2():63-4.
1997: G Capranico; G Giaccone; Franco Zunino; S Garattini; Maurizio D'Incalci
DNA topoisomerase II poisons and inhibitors.
Cancer chemotherapy and biological response modifiers 1997;17():114-31.
1997: P De Feudis; D Debernardis; P Beccaglia; M Valenti; E Graniela Siré; D Arzani; S Stanzione; Stefano Parodi; Maurizio D'Incalci; P Russo; Massimo Broggini
DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status.
British journal of cancer 1997;76(4):474-9.
1997: Cristina Sottani; Claudio Minoia; A Colombo; Massimo Zucchetti; Maurizio D'Incalci; R Fanelli
Structural characterization of mono- and dihydroxylated metabolites of paclitaxel in rat bile using liquid chromatography/ion spray tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 1997;11(9):1025-32.
1997: Maria Alfonsina Desiderio; D Bergamaschi; E Mascellani; P De Feudis; Eugenio Erba; Maurizio D'Incalci
Treatment with inhibitors of polyamine biosynthesis, which selectively lower intracellular spermine, does not affect the activity of alkylating agents but antagonizes the cytotoxicity of DNA topoisomerase II inhibitors.
British journal of cancer 1997;75(7):1028-34.
1996: G Belvedere; L Imperatori; G Damia; G Tagliabue; C Meijer; E G de Vries; Maurizio D'Incalci
In vitro and in vivo characterisation of low-resistant mouse reticulosarcoma (M5076) sublines obtained after pulse and continuous exposure to cisplatin.
European journal of cancer (Oxford, England : 1990) 1996;32A(11):2011-8.
1996: T Colombo; O Gonzalez Paz; M Zucchetti; A Maneo; Cristiana Sessa; A Goldhirsch; Maurizio D'Incalci; M Maneo
Paclitaxel induces significant changes in epidoxorubicin distribution in mice.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(8):801-5.
1996: F Vikhanskaya; Eugenio Erba; Maurizio D'Incalci; Massimo Broggini
Changes in cyclins and cyclin-dependent kinases induced by DNA damaging agents in a human ovarian cancer cell line expressing mutated or wild-type P53.
Experimental cell research 1996;227(2):380-5.
1996: D Gentili; Valentino Conter; Carmelo Rizzari; B Tschuemperlin; M Zucchetti; D Orlandoni; Maurizio D'Incalci; Giuseppe Masera
L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(7):725-30.
1996: Annamaria Codegoni; Fabio Landoni; S Lomonico; G Losa; Costantino Mangioni; M Taverna; V Lucchini; Maurizio D'Incalci
Interferon-beta can induce progesterone receptors in human endometrial adenocarcinoma.
Cancer 1996;78(3):448-53.
1996: Cristiana Sessa; J de Jong; Maurizio D'Incalci; S Hatty; Olivia Pagani; Franco Cavalli
Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(7):1123-7.
1996: G Damia; L Imperatori; M Stefanini; Maurizio D'Incalci
Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents.
International journal of cancer. Journal international du cancer 1996;66(6):779-83.
1996: T Colombo; O Gonzalez Paz; Maurizio D'Incalci
Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia.
British journal of cancer 1996;73(7):866-71.
1996: G Damia; L Imperatori; Lorenzo Citti; Laura Mariani; Maurizio D'Incalci
3-methyladenine-DNA-glycosylase and O6-alkyl guanine-DNA-alkyltransferase activities and sensitivity to alkylating agents in human cancer cell lines.
British journal of cancer 1996;73(7):861-5.
1996: Laura Popolo; F Viganò; Eugenio Erba; Nicola Mongelli; Maurizio D'Incalci
Effects of a novel DNA-damaging agent on the budding yeast Saccharomyces cerevisiae cell cycle.
Yeast (Chichester, England) 1996;12(4):349-59.
1996: Olivia Pagani; M Zucchetti; Cristiana Sessa; J de Jong; Maurizio D'Incalci; M De Fusco; A Kaeser-Fröhlich; Axel R Hanauske; Franco Cavalli
Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative.
Cancer chemotherapy and pharmacology 1996;38(6):541-7.
1995: M Zucchetti; Olivia Pagani; Valter Torri; Cristiana Sessa; Maurizio D'Incalci; M De Fusco; J de Jong; D Gentili; G Martinelli; Angelo Tinazzi
Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(12):1517-24.
1995: Sergio Marchini; O Gonzalez Paz; M Ripamonti; Cristina Geroni; A Bargiotti; M Caruso; S Todeschi; Maurizio D'Incalci; Massimo Broggini
Sequence-specific DNA interactions by novel alkylating anthracycline derivatives.
Anti-cancer drug design 1995;10(8):641-53.
1995: Eugenio Erba; E Mascellani; Antonio Pifferi; Maurizio D'Incalci
Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell line.
International journal of cancer. Journal international du cancer 1995;62(2):170-5.
1995: G Damia; Maurizio D'Incalci
Clinical pharmacokinetics of altretamine.
Clinical pharmacokinetics 1995;28(6):439-48.
1995: M Bellorini; V Moncollin; Maurizio D'Incalci; Nicola Mongelli; Roberto Mantovani
Distamycin A and tallimustine inhibit TBP binding and basal in vitro transcription.
Nucleic acids research 1995;23(10):1657-63.
1995: F Vikhanskaya; Maurizio D'Incalci; Massimo Broggini
Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes.
International journal of cancer. Journal international du cancer 1995;61(3):397-401.
1995: M G Donelli; M Zucchetti; A Robatto; V Perlangeli; Maurizio D'Incalci; G Masera; M R Rossi
Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia.
Medical and pediatric oncology 1995;24(3):154-9.
1995: M Cattabeni; Maurizio D'Incalci; Massimo Broggini
Differential expression of c-fos proto-oncogene in two subclones derived from a human ovarian cancer cell line.
Cellular and molecular biology (Noisy-le-Grand, France) 1995;41(2):255-63.
1995: M De Fusco; Maurizio D'Incalci; D Gentili; S Reichert; M Zucchetti
High-performance liquid chromatographic assay for the determination of the novel etoposide derivative dimethylaminoetoposide (NK611) and its metabolites in urine of cancer patients.
Journal of chromatography. B, Biomedical applications 1995;664(2):409-14.
1995: Massimo Broggini; H M Coley; Nicola Mongelli; E Pesenti; M D Wyatt; J A Hartley; Maurizio D'Incalci
DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin.
Nucleic acids research 1995;23(1):81-7.
1995: O Gonzalez; T Colombo; M De Fusco; L Imperatori; M Zucchetti; Maurizio D'Incalci
Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833.
Cancer chemotherapy and pharmacology 1995;36(4):335-40.
1994: Luisa Diomede; G Damia; Maurizio D'Incalci; L Imperatori; M Algeri; E J Modest; Mario Salmona
In vivo anti-tumor activity of synthetic ether lipids is not enhanced by pharmacological modulation of tumor lipid composition.
International journal of cancer. Journal international du cancer 1994;59(4):580-1.
1994: M Bonfanti; P Taverna; C Mangioni; G Losa; M Taverna; Maurizio D'Incalci
Interferon-beta does not change the level of O6-alkylguanine-DNA alkyltransferase in cancer patients' lymphocytes.
Anti-cancer drugs 1994;5(5):601-2.
1994: Massimo Broggini; Maurizio D'Incalci
Modulation of transcription factor--DNA interactions by anticancer drugs.
Anti-cancer drug design 1994;9(4):373-87.
1994: D Gentili; M Zucchetti; Valentino Conter; Giuseppe Masera; Maurizio D'Incalci
Determination of L-asparagine in biological samples in the presence of L-asparaginase.
Journal of chromatography. B, Biomedical applications 1994;657(1):47-52.
1994: F Vikhanskaya; Eugenio Erba; Maurizio D'Incalci; Massimo Broggini
Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53.
Nucleic acids research 1994;22(6):1012-7.
1994: M Zucchetti; M De Fusco; Cristiana Sessa; A Fröhlich; S Reichert; Maurizio D'Incalci
High-performance liquid chromatographic assay for the determination of the novel podophyllotoxin derivative dimethylaminoetoposide (NK611) in human plasma.
Journal of chromatography. B, Biomedical applications 1994;654(1):97-102.
1994: L Imperatori; G Damia; P Taverna; E Garattini; Lorenzo Citti; L Boldrini; Maurizio D'Incalci
3T3 NIH murine fibroblasts and B78 murine melanoma cells expressing the Escherichia coli N3-methyladenine-DNA glycosylase I do not become resistant to alkylating agents.
Carcinogenesis 1994;15(3):533-7.
1994: Cristina Geroni; E Pesenti; Massimo Broggini; G Belvedere; G Tagliabue; Maurizio D'Incalci; G Pennella; M Grandi
L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives.
British journal of cancer 1994;69(2):315-9.
1994: Eugenio Erba; S Sen; Cristiana Sessa; F L Vikhanskaya; Maurizio D'Incalci
Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid.
British journal of cancer 1994;69(2):205-11.
1994: S Sen; A Zocchetti; P Beccaglia; G Balconi; Eugenio Erba; Maurizio D'Incalci
Heterogeneous interaction of interferon-beta and taxol in human ovarian cancer cells in vitro.
European journal of cancer (Oxford, England : 1990) 1994;30A(6):892-3.
1994: Maria Ines Nicoletti; V Lucchini; Maurizio D'Incalci; Raffaella Giavazzi
Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts.
European journal of cancer (Oxford, England : 1990) 1994;30A(5):691-6.
1993: F Vikhanskaya; Maurizio D'Incalci; Massimo Broggini
Effects of DNA damaging agents on gene expression in two human cancer cell lines.
Cellular and molecular biology (Noisy-le-Grand, France) 1993;39(8):855-62.
1993: Maurizio D'Incalci
DNA-topoisomerase inhibitors.
Current opinion in oncology 1993;5(6):1023-8.
1993: S Fabbri; C Prontera; Massimo Broggini; Maurizio D'Incalci
Differential inhibition of the DNA binding of transcription factors NF kappa B and OTF-1 by nitrogen mustard and quinacrine mustard: transcriptional implications.
Carcinogenesis 1993;14(9):1963-7.
1993: Cristiana Sessa; M Zucchetti; Valter Torri; Olivia Pagani; Maurizio D'Incalci; D Gentili; Giovanni Martinelli; J deJong; M Alerci; Franco Cavalli
Chronic oral etoposide in small-cell lung cancer: clinical and pharmacokinetic results.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(7):553-8.
1993: G Balconi; G Damia; F Morali; M Marzola; G Tagliabue; Eugenio Erba; Maurizio D'Incalci
Cis-diamminedichloroplatinum sensitivity of murine reticulum sarcoma cells in primary culture and after in vitro passages.
In vitro cellular & developmental biology. Animal 1993;29A(8):617-9.
1993: M Marzola; M Zucchetti; N Colombo; Cristiana Sessa; Olivia Pagani; Maurizio D'Incalci; Franco Cavalli; C Mangioni
Low-dose oral etoposide in epithelial cancer of the ovary.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(6):517-9.
1993: Enrico Davoli; M Zucchetti; Maurizio D'Incalci; Cristiana Sessa; Franco Cavalli; Roberto Fanelli
Mass spectrometric identification and analysis of some aphidicolin metabolites in cancer patients.
Biological mass spectrometry 1993;22(6):351-7.
1993: G Tagliabue; Antonio Pifferi; G Balconi; E Mascellani; Cristina Geroni; Maurizio D'Incalci; Paolo Ubezio
Intracellular glutathione heterogeneity in L1210 murine leukemia sublines made resistant to DNA-interacting anti-neoplastic agents.
International journal of cancer. Journal international du cancer 1993;54(3):435-42.
1993: Moses Lee; A L Rhodes; M D Wyatt; Maurizio D'Incalci; S Forrow; John A Hartley
In vitro cytotoxicity of GC sequence directed alkylating agents related to distamycin.
Journal of medicinal chemistry 1993;36(7):863-70.
1993: H M Coley; Nicola Mongelli; Maurizio D'Incalci
The effects of a benzoic acid mustard derivative of distamycin A (FCE 24517) and related minor groove-binding distamycin analogues on the activity of major groove-binding alkylating agents.
Biochemical pharmacology 1993;45(3):619-26.
1993: Maria Ines Nicoletti; V Lucchini; G Massazza; B J Abbott; Maurizio D'Incalci; Raffaella Giavazzi
Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(2):151-5.
1993: Cristina Geroni; E Pesenti; G Tagliabue; D Ballinari; Nicola Mongelli; Massimo Broggini; Eugenio Erba; Maurizio D'Incalci; F Spreafico; M Grandi
Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies.
International journal of cancer. Journal international du cancer 1993;53(2):308-14.
1993: Maurizio D'Incalci; G Capranico; G Giaccone; F Zunino; S Garattini
DNA topoisomerase inhibitors.
Cancer chemotherapy and biological response modifiers 1993;14():61-85.
1993: D Gentili; M Zucchetti; Valter Torri; Cristiana Sessa; J de Jong; Franco Cavalli; Maurizio D'Incalci
A limited sampling model for the pharmacokinetics of etoposide given orally.
Cancer chemotherapy and pharmacology 1993;32(6):482-6.
1992: G Tagliabue; Lorenzo Citti; G Massazza; G Damia; Raffaella Giavazzi; Maurizio D'Incalci
Tumour levels of O6-alkylguanine-DNA-alkyltransferase and sensitivity to BCNU of human xenografts.
Anticancer research 1992;12(6B):2123-5.
1992: C Pardini; Antonio Piras; M Voliani; Giuseppe Rainaldi; Laura Mariani; P Taverna; Maurizio D'Incalci; Lorenzo Citti
Chinese hamster ovary cells deficient or proficient in O6-alkylguanine-DNA alkyltransferase activity are equally sensitive to X-rays.
Mutation research 1992;283(2):125-9.
1992: P Taverna; Carlo V Catapano; Lorenzo Citti; M Bonfanti; Maurizio D'Incalci
Influence of O6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas.
Anti-cancer drugs 1992;3(4):401-5.
1992: P Coccia; Riccardo Bertini; P Pagani; C Marinello; P Taverna; P Villa; Maurizio D'Incalci
O6-alkylguanine DNA alkyltransferase is induced by human recombinant interferon-alpha A/D in mouse liver.
Journal of interferon research 1992;12(3):173-6.
1992: P Taverna; E Garattini; Lorenzo Citti; G Damia; Maurizio D'Incalci
Expression of E. coli tag gene encoding 3-methyladenine glycosylase I in NIH-3T3 murine fibroblasts.
Biochemical and biophysical research communications 1992;185(1):41-6.
1992: M G Donelli; M Zucchetti; Maurizio D'Incalci
Do anticancer agents reach the tumor target in the human brain?
Cancer chemotherapy and pharmacology 1992;30(4):251-60.
1992: P Coccia; S Sen; Eugenio Erba; P Pagani; C Marinello; Maurizio D'Incalci
O6-Alkylguanine-DNA alkyltransferase content in synchronised human cancer cells.
Cancer chemotherapy and pharmacology 1992;30(1):77-80.
1992: M Bonfanti; P Taverna; L Chiappetta; P Villa; Maurizio D'Incalci; R Bagnati; Roberto Fanelli
DNA damage induced by alachlor after in vitro activation by rat hepatocytes.
Toxicology 1992;72(2):207-19.
1992: G Damia; G Tagliabue; M Zucchetti; Enrico Davoli; Cristiana Sessa; Franco Cavalli; Maurizio D'Incalci
Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin.
Cancer chemotherapy and pharmacology 1992;30(6):459-64.
1992: Eugenio Erba; S Sen; Aurelio Lorico; Maurizio D'Incalci
Potentiation of etoposide cytotoxicity against a human ovarian cancer cell line by pretreatment with non-toxic concentrations of methotrexate or aphidicolin.
European journal of cancer (Oxford, England : 1990) 1992;28(1):66-71.
1991: M Bonfanti; Massimo Broggini; C Prontera; Maurizio D'Incalci
O6-methylguanine inhibits the binding of transcription factors to DNA.
Nucleic acids research 1991;19(20):5739-42.
1991: Maurizio D'Incalci; Henk J Broxterman; C K van Kalken
AACR special conference in cancer research. Membrane transport in multidrug resistance, development, and disease. American Association for Cancer Research.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(9):635-9.
1991: Cristiana Sessa; M Zucchetti; Enrico Davoli; R Califano; Franco Cavalli; S Frustaci; L Gumbrell; A Sulkes; B Winograd; Maurizio D'Incalci
Phase I and clinical pharmacological evaluation of aphidicolin glycinate.
Journal of the National Cancer Institute 1991;83(16):1160-4.
1991: M Ponti; S M Forrow; Robert Souhami; Maurizio D'Incalci; John A Hartley
Measurement of the sequence specificity of covalent DNA modification by antineoplastic agents using Taq DNA polymerase.
Nucleic acids research 1991;19(11):2929-33.
1991: Enzo Galligioni; M Quaia; A Spada; Diana Crivellari; D Favaro; Roberto Sorio; R Talamini; Maurizio D'Incalci; P Allavena; G Damia
Natural killer (NK) and lymphokine activated killer (LAK) cell activity in patients (PTS) treated with flavone acetic acid (FAA).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(2):145-50.
1991: Maurizio D'Incalci; P Taverna; Eugenio Erba; S Filippeschi; D Potenza; Laura Mariani; Lorenzo Citti; Carlo V Catapano
O6-methylguanine and temozolomide can reverse the resistance to chloroethylnitrosoureas of a mouse L1210 leukemia.
Anticancer research 1991;11(1):115-21.
1991: M Zucchetti; C Rossi; R Knerich; M G Donelli; G Butti; V Silvani; Paolo Gaetani; Maurizio D'Incalci
Concentrations of VP16 and VM26 in human brain tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(1):63-6.
1991: Massimo Broggini; Eugenio Erba; M Ponti; D Ballinari; Cristina Geroni; F Spreafico; Maurizio D'Incalci
Selective DNA interaction of the novel distamycin derivative FCE 24517.
Cancer research 1991;51(1):199-204.
1990: G Damia; A Garofalo; C Rossi; Raffaella Giavazzi; Maurizio D'Incalci
Flavone acetic acid pharmacokinetics in nude mice.
Anticancer research 1990;10(2A):437-9.
1990: N Laudonio; Gabriella Zupi; E Erba; Carlo Leonetti; Maurizio D'Incalci
Synergism between 5-fluorouracil and N-methylformamide in HT29 human colon cancer line.
British journal of cancer 1990;61(3):377-81.
1990: Massimo Broggini; John A Hartley; William Mattes; M Ponti; K W Kohn; Maurizio D'Incalci
DNA damage and sequence specificity of DNA binding of the new anti-cancer agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate)
British journal of cancer 1990;61(2):285-9.
1990: Paola Allavena; P Pirovano; C Bonazzi; N Colombo; A Mantovani; Maurizio D'Incalci
In vitro and in vivo effects of cisplatin on the generation of lymphokine-activated killer cells.
Journal of the National Cancer Institute 1990;82(2):139-42.
1990: Riccardo Bertini; P Coccia; P Pagani; C Marinello; Mario Salmona; Maurizio D'Incalci
Interferon inducers increase O6-alkylguanine-DNA alkyltransferase in the rat liver.
Carcinogenesis 1990;11(1):181-3.
1990: S Sen; Eugenio Erba; Maurizio D'Incalci
Synchronisation of cancer cell lines of human origin using methotrexate.
Cytometry 1990;11(5):595-602.
1990: G Damia; A Freschi; Roberto Sorio; A Braida; G Caruso; M Quaia; Silvio Monfardini; Maurizio D'Incalci
Flavone acetic acid distribution in human malignant tumors.
Cancer chemotherapy and pharmacology 1990;26(1):67-70.
1990: L Zanette; M Zucchetti; A Freshi; D Erranti; U Tirelli; Maurizio D'Incalci
Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients.
Cancer chemotherapy and pharmacology 1990;25(6):445-8.
1990: L Capolongo; G Belvedere; Maurizio D'Incalci
DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and -resistant human colon carcinoma cells.
Cancer chemotherapy and pharmacology 1990;25(6):430-4.
1990: P G Montaldo; F Figoli; M L Zanette; Roberto Sorio; M Zucchetti; U Tirelli; Maurizio D'Incalci
Pharmacokinetics of intrapleural versus intravenous etoposide (VP 16) and teniposide (VM 26) in patients with malignant pleural effusion.
Oncology 1990;47(1):55-61.
1990: G Damia; G Tagliabue; P Allavena; Maurizio D'Incalci
Flavone acetic acid antitumour activity against a mouse pancreatic adenocarcinoma is mediated by natural killer cells.
Cancer immunology, immunotherapy : CII 1990;32(4):241-4.
1990: M Limonta; A Biondi; Giovanni Giudici; G Specchia; Carlo V Catapano; G Masera; Tiziano Barbui; Maurizio D'Incalci
Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells.
Cancer chemotherapy and pharmacology 1990;26(5):340-2.
1989: Paolo Ubezio; M Limonta; Maurizio D'Incalci; G Damia; G Masera; Giovanni Giudici; J S Wolverton; William T Beck
Failure to detect the P-glycoprotein multidrug resistant phenotype in cases of resistant childhood acute lymphocytic leukaemia.
European journal of cancer & clinical oncology 1989;25(12):1895-9.
1989: G Belvedere; A Suarato; Cristina Geroni; FC Giuliani; Maurizio D'Incalci
Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo).
Biochemical pharmacology 1989;38(21):3713-21.
1989: G Massazza; A Tomasoni; V Lucchini; Paola Allavena; E Erba; Nicoletta Colombo; A Mantovani; Maurizio D'Incalci; Costantino Mangioni; Raffaella Giavazzi
Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy.
International journal of cancer. Journal international du cancer 1989;44(3):494-500.
1989: Eugenio Erba; Paolo Ubezio; S Pepe; M Vaghi; Silvia Marsoni; W Torri; Costantino Mangioni; Fabio Landoni; Maurizio D'Incalci
Flow cytometric analysis of DNA content in human ovarian cancers.
British journal of cancer 1989;60(1):45-50.
1989: M Zucchetti; Carlo V Catapano; S Filippeschi; Eugenio Erba; Maurizio D'Incalci
Temozolomide induced differentiation of K562 leukemia cells is not mediated by gene hypomethylation.
Biochemical pharmacology 1989;38(13):2069-75.
1989: P G Montaldo; Maurizio D'Incalci
High-performance liquid chromatographic determination of 5-bromodeoxyuridine in human plasma.
Journal of chromatography 1989;491(1):129-38.
1989: A Ferrari; G Damia; Eugenio Erba; C Rossi; R Mandelli; Maurizio D'Incalci
Characterization of a novel mouse reticular cell sarcoma M5076 subline resistant to cisplatin.
International journal of cancer. Journal international du cancer 1989;43(6):1091-7.
1989: Serenella Rotondo; M Zucchetti; Cristiana Sessa; Maurizio D'Incalci; Emilio Benfenati; Roberto Fanelli
A gas chromatographic mass spectrometric assay for the determination of aphidicolin in plasma of cancer patients.
Journal of pharmaceutical sciences 1989;78(5):399-401.
1989: Emilio Benfenati; M Zucchetti; Maurizio D'Incalci
Identification of microsomal metabolites of spirogermanium.
Anticancer research 1989;9(2):507-10.
1989: Massimo Broggini; M Ponti; S Ottolenghi; Maurizio D'Incalci; Nicola Mongelli; Roberto Mantovani
Distamycins inhibit the binding of OTF-1 and NFE-1 transfactors to their conserved DNA elements.
Nucleic acids research 1989;17(3):1051-9.
1989: Maurizio D'Incalci; G Balconi; Massimo Broggini; T Colombo; M Marzola; F Morali; Y Pang; S Sen; L Spinelli
Problems in the design of anticancer agents.
Cancer surveys 1989;8(3):535-55.
1989: Emilio Benfenati; P Farina; T Colombo; De Bellis Gianluca; M V Capodiferro; Maurizio D'Incalci
Metabolism and pharmacokinetics of p-(3,3-dimethyl-1-triazeno) benzoic acid in M5076 sarcoma-bearing mice.
Cancer chemotherapy and pharmacology 1989;24(6):354-8.
1989: C Mannironi; E Erba; D Corda; L Gianellini; Maurizio D'Incalci
Changes in the synthesis of histone H1(0) and H1 in rat FRTL-5 thyroid cells exposed to thyrotropin.
Life sciences 1989;45(23):2209-16.
1988: Massimo Broggini; M Grandi; Paolo Ubezio; Cristina Geroni; FC Giuliani; Maurizio D'Incalci
Intracellular doxorubicin concentrations and drug-induced DNA damage in a human colon adenocarcinoma cell line and in a drug-resistant subline.
Biochemical pharmacology 1988;37(23):4423-31.
1988: Maurizio D'Incalci; Lorenzo Citti; P Taverna; Carlo V Catapano
Importance of the DNA repair enzyme O6-alkyl guanine alkyltransferase (AT) in cancer chemotherapy.
Cancer treatment reviews 1988;15(4):279-92.
1988: S Filippeschi; T Colombo; D Bassani; L De Francesco; P Arioli; Maurizio D'Incalci; I Bartosek; A Guaitani
Antitumor activity of the novel nitrosourea S10036 in rodent tumors.
Anticancer research 1988;8(6):1351-4.
1988: C Mannironi; Maurizio D'Incalci
Doxorubicin induces the acetylation of histone H1 in a human colon cancer cell line (LoVo/DX) selected for resistance to the drug, but not in the sensitive parental line (LoVo).
Biochemical and biophysical research communications 1988;155(3):1221-9.
1988: C Mannironi; V Rossi; Andrea Biondi; Paolo Ubezio; Giovanni Giudici; G Masera; Maurizio D'Incalci
Comparison of histone variant synthesis in human lymphocytic leukemia cells and in normal lymphocytes.
Cancer research 1988;48(13):3670-5.
1988: G Balconi; Massimo Broggini; Eugenio Erba; Maurizio D'Incalci; N Colombo; Costantino Mangioni; F Bertolero
Human ovarian tumors in primary culture: growth, characterization and initial evaluation of the response to cis platinum treatment in vitro.
International journal of cancer. Journal international du cancer 1988;41(6):809-18.
1988: Carlo V Catapano; Paolo Ubezio; V Rossi; Valentino Conter; M Jancovich; Maurizio D'Incalci
Intracellular drug concentration and DNA damage in human childhood leukemic cells exposed to doxorubicin.
Biochemical pharmacology 1988;37(9):1863-4.
1988: Massimo Broggini; G Balconi; F Bertolero; Eugenio Erba; F Landoni; Costantino Mangioni; Maurizio D'Incalci
DNA interstrand cross-links induced by cis-dichlorodiammine platinum in ovarian cancer cells growing in primary culture.
Biochemical pharmacology 1988;37(9):1835-6.
1988: Cristiana Sessa; M Zucchetti; M Ginier; Y Willems; Maurizio D'Incalci; Franco Cavalli
Phase I study of the antifolate N10-propargyl-5,8-dideazafolic acid, CB 3717.
European journal of cancer & clinical oncology 1988;24(4):769-75.
1988: Raffaella Giavazzi; A Garofalo; G Damia; S Garattini; Maurizio D'Incalci
Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts.
British journal of cancer 1988;57(3):277-80.
1988: Eugenio Erba; Paolo Ubezio; Massimo Broggini; M Ponti; Maurizio D'Incalci
DNA damage, cytotoxic effect and cell-cycle perturbation of Hoechst 33342 on L1210 cells in vitro.
Cytometry 1988;9(1):1-6.
1988: M Zucchetti; Maurizio D'Incalci; Y Willems; Franco Cavalli; Cristiana Sessa
Lack of effect of cisplatin on i.v. L-PAM plasma pharmacokinetics in ovarian cancer patients.
Cancer chemotherapy and pharmacology 1988;22(1):87-9.
1988: G Damia; M L Zanette; C Rossi; R Mandelli; A Ferrari; Maurizio D'Incalci
Dose-dependent pharmacokinetics of flavone acetic acid in mice.
Cancer chemotherapy and pharmacology 1988;22(1):47-50.
1987: C Rossi; G Gasparini; L Canobbio; Enzo Galligioni; R Volpe; E Candiani; G Toffoli; Maurizio D'Incalci
Doxorubicin distribution in human breast cancer.
Cancer treatment reports 1987;71(12):1221-6.
1987: L Capolongo; G Balconi; Paolo Ubezio; R Giavazzi; G Taraboletti; A Regonesi; O C Yoder; Maurizio D'Incalci
Antiproliferative properties of flavone acetic acid (NSC 347512) (LM 975), a new anticancer agent.
European journal of cancer & clinical oncology 1987;23(10):1529-35.
1987: C Mannironi; V Rossi; Andrea Biondi; Paolo Ubezio; G Masera; Tiziano Barbui; Maurizio D'Incalci
Histone H1(0) is synthesized by human lymphocytic leukemia cells but not by normal lymphocytes.
Blood 1987;70(4):1203-7.
1987: Carlo V Catapano; Massimo Broggini; Eugenio Erba; M Ponti; Laura Mariani; Lorenzo Citti; Maurizio D'Incalci
In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas.
Cancer research 1987;47(18):4884-9.
1987: M L Zanette; U Tirelli; Roberto Sorio; D Zadro; F Figoli; Silvio Monfardini; Maurizio D'Incalci
Pharmacokinetics of 7-con-O-methylnogarol in patients with solid tumors.
Cancer chemotherapy and pharmacology 1987;20(1):67-70.
1987: F Figoli; M L Zanette; U Tirelli; Roberto Sorio; Chiara Lestuzzi; R Urso; Silvio Monfardini; Maurizio D'Incalci
Pharmacokinetics of VM 26 given intrapericardially or intravenously in patients with malignant pericardial effusion.
Cancer chemotherapy and pharmacology 1987;20(3):239-42.
1986: Maurizio D'Incalci; C Rossi; M Zucchetti; R Urso; Franco Cavalli; C Mangioni; Y Willems; Cristiana Sessa
Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function.
Cancer research 1986;46(5):2566-71.
1986: T Colombo; M Broggini; M Vaghi; G Amato; Eugenio Erba; Maurizio D'Incalci
Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse.
European journal of cancer & clinical oncology 1986;22(2):173-9.
1986: P Farina; L Torti; R Urso; J K Horton; A Gescher; Maurizio D'Incalci
Comparison of metabolism and activity of an aryldimethyltriazene and an aryldiethyltriazene.
Biochemical pharmacology 1986;35(2):209-15.
1985: P Farina; Emilio Benfenati; L Lassiani; C Nisi; Maurizio D'Incalci
High-performance liquid chromatographic assay for the determination of p-(3,3-dimethyl-1-triazeno)benzoic acid in mouse plasma.
Journal of chromatography 1985;345(2):323-31.
1985: Maurizio D'Incalci; C Rossi; Cristiana Sessa; R Urso; M Zucchetti; P Farina; C Mangioni
Pharmacokinetics of teniposide in patients with ovarian cancer.
Cancer treatment reports 1985;69(1):73-7.
1984: C Rossi; M Zucchetti; Cristiana Sessa; R Urso; C Mangioni; Maurizio D'Incalci
Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients.
Cancer chemotherapy and pharmacology 1984;13(3):211-4.
1983: Maurizio D'Incalci; L Torti; G Damia; Eugenio Erba; L Morasca; S Garattini
Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide.
Cancer research 1983;43(12 Pt 1):5674-80.
1983: P Farina; Emilio Benfenati; R Reginato; L Torti; Maurizio D'Incalci; Michael Threadgill; A Gescher
Metabolism of the anticancer agent 1-(4-acetylphenyl)-3,3-dimethyltriazene.
Biomedical mass spectrometry 1983;10(8):485-8.
1983: Eugenio Erba; Paolo Ubezio; T Colombo; M Broggini; L Torti; M Vaghi; Maurizio D'Incalci; L Morasca
Flow-cytometric analysis of DNA distribution after VP16-213 treatment of Lewis lung carcinoma.
Cancer chemotherapy and pharmacology 1983;10(3):208-11.
1982: P Farina; A Gescher; J A Hickman; J K Horton; Maurizio D'Incalci; D Ross; M F Stevens; L Torti
Studies of the mode of action of antitumour triazenes and triazines--IV. The metabolism of 1-(4-acetylphenyl)-3,3-dimethyltriazene.
Biochemical pharmacology 1982;31(10):1887-92.
1982: Maurizio D'Incalci; Eugenio Erba; M Vaghi; L Morasca
In vitro cytotoxicity of VP 16 on primary tumor and metastasis of Lewis lung carcinoma.
European journal of cancer & clinical oncology 1982;18(4):377-80.
1982: T Colombo; M Broggini; L Torti; Eugenio Erba; Maurizio D'Incalci
Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice.
Cancer chemotherapy and pharmacology 1982;7(2-3):127-31.
1981: T Colombo; L Torti; Maurizio D'Incalci
Dose-dependent pharmacokinetics of PMM in the rat.
Cancer chemotherapy and pharmacology 1981;5(3):201-3.
1980: Maurizio D'Incalci; Eugenio Erba; G Balconi; L Morasca; S Garattini
Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites.
British journal of cancer 1980;41(4):630-5.
1980: L Morasca; G Balconi; Eugenio Erba; Maurizio D'Incalci; L Ottolenghi; A Salmona; S Garattini
Pharmacokinetic approach to in vitro testing of ovarian cancer cell sensitivity.
Oncology 1980;37(3):169-73.